During the VERTIS SITA trial, similar doses of the Ertugliflozin have been tested along with the Januvia. When compared to the placebo and Januvia, similar results were observed. The drug’s safety profile is consistent with the other SGLT2 drugs.
As the number of diabetes cases continues to increase, drug researchers are committed to meeting the patients’ needs. Thus, additional treatment options are being made to help in managing the condition. Furthermore, medical experts added that the findings have underscored the potential of Ertugliflozin as a treatment option for those with Type 2 Diabetes. The Ertugliflozin were expected to be available in the US market in early 2018. They will be marketed in the United States under the brand names Segluromet and Steglujan.
